Fierce Pharma August 1, 2022
Pharma’s reputation may have soared amid the pandemic, but that came with a brighter spotlight on diversity, equity and inclusion issues. In recent years, pharma has been trying to incorporate DEI more deeply into its corporate psyche.
Long accused of paying lip service to DEI issues, the rise of the Black Lives Matter movement combined with a woeful under-representation of ethnic diversity in many early COVID vaccine trials in 2020 made these issues of central concern to companies.
In the past, we’ve focused our reports on environment, social and governance issues. This year, given its sharper focus, our report concentrates solely on DEI ratings based on an analysis from reputation intelligence firm alva.
Today's Sponsors
Today's Sponsor